- Home
- ALMU vs LCTX Comparison
ALMU vs LCTX Comparison
Compare ALMU & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALMU
- LCTX
- Stock Information
- Founded
- ALMU 2019
- LCTX 1990
- Country
- ALMU United States
- LCTX United States
- Employees
- ALMU N/A
- LCTX N/A
- Industry
- ALMU Semiconductors
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALMU Technology
- LCTX Health Care
- Exchange
- ALMU Nasdaq
- LCTX Nasdaq
- Market Cap
- ALMU 295.5M
- LCTX 274.0M
- IPO Year
- ALMU N/A
- LCTX N/A
- Fundamental
- Price
- ALMU $15.44
- LCTX $1.34
- Analyst Decision
- ALMU Strong Buy
- LCTX Strong Buy
- Analyst Count
- ALMU 2
- LCTX 4
- Target Price
- ALMU $25.50
- LCTX $4.25
- AVG Volume (30 Days)
- ALMU 309.7K
- LCTX 1.6M
- Earning Date
- ALMU 09-09-2025
- LCTX 08-12-2025
- Dividend Yield
- ALMU N/A
- LCTX N/A
- EPS Growth
- ALMU N/A
- LCTX N/A
- EPS
- ALMU N/A
- LCTX N/A
- Revenue
- ALMU $4,665,000.00
- LCTX $10,914,000.00
- Revenue This Year
- ALMU $60.71
- LCTX N/A
- Revenue Next Year
- ALMU $107.42
- LCTX $178.80
- P/E Ratio
- ALMU N/A
- LCTX N/A
- Revenue Growth
- ALMU 407.62
- LCTX 76.43
- 52 Week Low
- ALMU $2.50
- LCTX $0.37
- 52 Week High
- ALMU $25.88
- LCTX $1.42
- Technical
- Relative Strength Index (RSI)
- ALMU 40.81
- LCTX 64.60
- Support Level
- ALMU $13.02
- LCTX $1.20
- Resistance Level
- ALMU $18.78
- LCTX $1.28
- Average True Range (ATR)
- ALMU 1.73
- LCTX 0.07
- MACD
- ALMU -0.62
- LCTX 0.00
- Stochastic Oscillator
- ALMU 23.40
- LCTX 69.64
About ALMU Aeluma Inc. Common Stock
Aeluma Inc is a semiconductor company specializing in sensors and communications. It is developing sensor technology for mobile devices and vehicles. The company develops novel optoelectronic devices for sensing and communications applications. The company manufactures devices using high-performance compound semiconductor materials on large-diameter substrates that are commonly used to manufacture mass-market microelectronics. The applications include mobile, automotive, AI, defense & aerospace, communication, AR/VR and quantum computing.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.